SSRIs significantly increase the risk of both serious and non-serious adverse events .
The potential small beneficial effects seem to be outweighed by harmful effects .
Background The evidence on selective serotonin reuptake inhibitors ( SSRIs ) for major depressive disorder is unclear .
Methods Our objective was to conduct a systematic review assessing the effects of SSRIs versus placebo , ‘ active ’ placebo , or no intervention in adult participants with major depressive disorder .
A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.
The current study sought to test the efficacy and safety of the novel selective norepinephrine reuptake inhibitor LY2216684 compared to placebo in patients with major depressive disorder ( MDD ) .  Escitalopram was used as a control for assay sensitivity . Adult out patients with MDD , confirmed at screening by the Mini International Neuropsychiatric Interview , a Self-Rated Quick Inventory of Depressive Symptomatology ( QIDS-SR ) score of at least 12 and a Clinical Global Impression-Severity Score of at least 4 , were r and omly assigned to LY2216684 ( N=269 ) , placebo ( N=138 ) , or escitalopram ( N=62 ) .  Efficacy , safety , and tolerability outcomes were compared during 8 weeks of double-blind treatment . LY2216684 plasma concentrations were measured . LY2216684 did not show statistically significant improvement from baseline compared to placebo in the primary analysis of the Hamilton depression rating scale ( HAM-D(17 ) ) total score . Escitalopram demonstrated significant improvement compared to placebo on the HAM-D(17 ) total score , suggesting adequate assay sensitivity . Both LY2216684 and escitalopram showed statistically significant improvement from baseline on the patient-rated QIDS-SR total score compared to placebo .  Headache , nausea , constipation , dry mouth , and insomnia were the most frequently reported adverse events in the LY2216684 group . A 3 - 6 beats per minute mean increase from baseline in pulse rate was observed in the LY2216684 group .  LY2216684 plasma concentrations increased as the dose increased from 3 mg to 12 mg . The results of this initial investigation of LY2216684 's efficacy suggest that it may have antidepressant potential . More definitive data to confirm this is necessary . Its safety profile does not preclude further clinical development
SSRIs significantly increase the risk of both serious and non-serious adverse events .
The potential small beneficial effects seem to be outweighed by harmful effects .
Background The evidence on selective serotonin reuptake inhibitors ( SSRIs ) for major depressive disorder is unclear .
Methods Our objective was to conduct a systematic review assessing the effects of SSRIs versus placebo , ‘ active ’ placebo , or no intervention in adult participants with major depressive disorder .